Teva Pharmaceutical Industries (TEVA) Short-term Investments (2009 - 2011)

Teva Pharmaceutical Industries (TEVA) has reported Short-term Investments for 3 consecutive years, with $38.0 million the latest figure, recorded in Q3 2011.

• Quarterly Short-term Investments rose 80.95% year-over-year to $38.0 million in Q3 2011, while the trailing twelve-month figure through Sep 2011 was $38.0 million (up 80.95% YoY) and the FY2010 annual result came in at $36.0 million, down 85.77% from the prior year.
• Short-term Investments advanced to $38.0 million in Q3 2011 per TEVA's latest filing, from $18.0 million in the prior quarter.
• Over the last five years, Short-term Investments for TEVA reached as high as $337.0 million in Q1 2010 and fell as low as $18.0 million in Q2 2011.
• A 3-year average of $93.3 million and a median of $38.0 million in 2011 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2010 — Short-term Investments jumped 574.0% — and 2011, when it slumped 91.99%.
• Year by year, Short-term Investments stood at $253.0 million in 2009, then slumped by 85.77% to $36.0 million in 2010, then climbed by 5.56% to $38.0 million in 2011.
• According to Business Quant data, Short-term Investments over the past three periods registered $38.0 million, $18.0 million, and $27.0 million for Q3 2011, Q2 2011, and Q1 2011 respectively.